ER-α 36 is another splicing variant; it plays an important role, inhibiting wild-type ER-α (ER-α66) and ER-β, being involved in the resistance of breast cancer to hormonal treatment [116] and in testosterone-initiated carcinogenesis [117]. Here, ESR1 is linked to breast carcinoma.